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Abstract
Monogenic inherited hypertension, which is caused by a single gene mutation, 
generally conforms to the Mendel’s law, but its phenotype is affected by environ-
mental factors as well. This type of hypertension is characterized by early onset 
(more common in adolescents), family history, severe hypertension, or refractory 
hypertension. It is often accompanied by abnormal hormone level and biochemical 
indicators, including low activity of plasma renin, abnormal potassium, and acid-
base metabolization disorder. For adolescents with a family history of moderate to 
severe hypertension, hormone level (including plasma renin-angiotensin-aldoste-
rone, cortisol, and sex hormone) and blood electrolytes should be measured and 
the detailed diagnosis should be determined according to medical history, physical 
signs, and test results. Currently, 17 kinds of monogenic hereditary hyperten-
sion have been clearly determined. Thanks to the development of gene detection 
technology, the diagnostic level of monogenic inherited hypertension has greatly 
improved and the pathogenesis has been gradually clarified. Our review mainly 
discussed the research progress in this field.
Keywords: monogenic hereditary disease, hypertension, rennin, potassium,  
gene detection
1. Introduction
Monogenic inherited hypertension, which was caused by a single gene muta-
tion, generally conforms to the Mendel’s law, but the phenotype is also affected by 
environmental factors. It can be identified in a large and heterogeneous family of 
hypertensive patients with highly specific etiologies and similar clinical manifesta-
tions [1]. It is characterized by early onset (more common in adolescents), familial 
aggregation, and refractory hypertension and the renin-angiotensin-aldosterone 
system features typical changes in almost every case. In the following report, we 
will review some well-characterized disorders.
1.1 Liddle syndrome
Liddle syndrome (LS), known as pseudohypoaldosteronism type I, which was 
firstly reported by Liddle in 1963 [2], is an autosomal dominant genetic form of 
low renin arterial hypertension caused by germline mutations in the SCNN1A, 
SCNN1B, and SCNN1G genes that encode the α, β, and γ subunits of the epithelial 
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sodium channel (ENaC), respectively. The prevalence of LS across the general 
hypertensive population still remains unknown. Three small single-center studies 
have estimated the prevalence to be about 0.91 [3], 1.52 [4], and 6% [5] among 
hypertensive patients with genetic testing and phenotypical LS, respectively.
The mutation gene was the nonsense p.Agr566* substitution of the β subunit, 
firstly described in the large kindred by Liddle et al. and subsequently Botero-Velez 
et al. [6] found that the mutation causes a truncation of the C-terminus of the β 
subunit with a loss of the PY motif. The first germinal mutation of SCNN1G gene, 
resulting in the nonsense substitution p.Trp573*, was identified by Hansson et al. 
in 1995 [7], the mutation erases the γ subunit’s C-terminus, causing the loss of the 
PY motif. Different rare variants of SCNN1A have also been associated with pseu-
dohypoaldosteronism type I, with the possibility of the compound heterozygotes in 
different ENaC subunits contributing to its phenotype in a digenic manner.
Recently, a germline mutation in the α subunit (p.Cys479Arg) was identified 
in a Caucasian family suffering from LS [8]. This missense mutation increases 
the open conformation of the channel, resulting in a two-fold increase in Na+ 
current, without affecting channel density at the plasma membrane. It has been 
reported that there are 31 different mutations responsible for LS in 72 families 
so far [9].
Most of these mutations are frameshift, missense, or nonsense, impairing the 
PY motif and increasing ENaC expression at the distal nephron apical membrane, 
following a subsequent increase in Na+ reabsorption. LS is characterized by resistant 
and early onset salt-sensitive arterial hypertension clinically, often associated with a 
family history of early onset hypertension and sudden death.
On average, hypertension develops around the second decade of life 
(15.5 ± 3.3 years) [10], with variation in the age of onset and severity of hyperten-
sion [6]. Without treatment, subjects will present with complications of severe 
hypertension during the third or fourth decade of life. Despite the typical phe-
notype presenting with severe hypertension and hypokalemia, the disease can be 
clinically heterogeneous, even with mild phenotypes.
Biochemically, the characteristic findings are hypokalemia, metabolic alkalo-
sis, suppressed plasma renin activity (PRA), and low serum aldosterone levels. 
The diagnosis of LS is based on gene sequencing of SCNN1A, SCNN1B, and 
SCNN1G. Considering the autosomal dominant inheritance (50% risk of transmis-
sion) and the variable phenotype reported in some families, genetic screening also 
has to be performed in first-degree relatives of a mutation carrier.
As for the treatment of LS, amiloride which is a potassium-sparing diuretics, 
or triamterene which a direct ENaC inhibitor, combined with a low sodium diet, 
mitigate sodium-sensitive hypertension by inhibiting sodium transport through 
ENaC. The drug effect is rapid and exceptionally good. While spironolactone, 
another potassium-sparing diuretics, has no therapeutic effect on LS.
1.2 Gordon syndrome
Gordon syndrome (GS), also known as pseudohypoaldosteronism type II or 
familial hyperkalemia hypertension, is a rare form of monogenic hypertension 
characterized by low renin, hyperkalemia, hyperchloremic metabolic acidosis, and 
normal glomerular filtration rate [11].
This phenotype was first discovered in 1964 by Paver and Pauline [12], and 
Gordon [13] identified the phenotype to be an inheritable disorder based on a study 
of several pedigrees later in the 1980s. The hyperkalemia is a useful discriminator, 
distinguishing GS from other forms of monogenic hypertension which present with 
normokalemia or hypokalemia [14].
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Although GS is considered to be an autosomal dominant inherited disease, new 
molecular studies reported some recessive cases [15]. Mutations in four genes such 
as WNK1 (pseudohypoaldosteronism type IIC), WNK4 (pseudohypoaldosteronism 
type IIB) [16], CUL3 (pseudohypoaldosteronism type IIE), and KLHL3 (pseudohy-
poaldosteronism type IID) [17] have been identified to be responsible for GS.
WNKs belong to a large family of serine-threonine protein kinases with pleiotro-
pic effects. The WNK kinases (encoded by the WNK1 and WNK4 genes) regulate the 
expression of the Na+/Cl−-cotransporter (NCC) in the distal nephron and the Na+-
K+-2Cl−-cotransporter (NKCC2) in the thick ascending limb of Henle’s loop, which 
play an important role in the development of hypertension in patients with GS.
However, WNKs phosphorylate these transporters indirectly, and it is contro-
versial how WNKs regulate the transporters and how mutations of WNKs cause 
activation of the transporters.
Recently, it has been discovered that STE20/SPS1-related proline/alanine-rich 
kinase and oxidative stress-responsive kinase 1 which are two other serine/threo-
nine kinases downstream of WNKs, phosphorylate and activate NCC and NKCC2 
actually [18–20]. While the scaffold protein Cullin3 and the adaptor protein Kelch3 
(encoded by the CUL3 and KLHL3 genes, respectively), which accounted for the 
majority of pathogenic mutations [18], are involved in the ubiquitination and 
proteasomal degradation of the WNK kinases [21].
Therefore, loss-of-function mutations in these genes result in inhibited deg-
radation of WNKs in the distal nephron and thus upregulation of NCC activity. 
Different mutant genes are significantly correlated with the clinical manifestations 
of GS, which can be sorted as CLU3 > KLHL3 > WNK4 > WNK1 according to the 
age of onset and clinical manifestations.
CLU3 mutants develop early onset, most of them present hypertension when 
they are minors, and show severe hyperkalemia and metabolic acidosis. Patients 
with WNK1 may not develop hypertension until late adulthood, and the clinical 
symptoms are relatively mild, but occasionally they are severe accompanied by 
periodic paralysis.
Affected subjects have suppressed renin levels consistent with salt-loaded state, 
while the aldosterone levels are typically low despite their hyperkalemia. Dietary 
sodium restriction (20 mmol/day) and/or low doses of thiazide diuretics can reverse 
hypertension and hyperkalemia of patients with GS [13, 22].
1.3 Apparent mineralocorticoid excess syndrome
Apparent mineralocorticoid excess (AME) syndrome is an autosomal recessive 
disorder due to the loss of functional mutations in HSD11B2 gene on chromosome 
16q22, and it is first described in the late 1970s [23].
Approximately 40 causative mutations in HSD11B2 have been identified in 100 
AME patients worldwide [24]. In AME syndrome, the function of 11β-HSD2 with a 
potential age-dependent decline in the activity [25] is impaired, and therefore the 
MR, which has the same affinity for both aldosterone and cortisol, is protected from 
cortisol activation by 11β-HSD2 activity under physiological conditions, is occupied 
and activated by cortisol, resulting in hypertension.
Affected patients display low birth weight, severe hypertension, polyuria and 
polydipsia, hypokalemia, low PRA, and low aldosterone in the classical AME syn-
drome which is caused by absolutely or essentially absent of the 11β-HSD2 activity.
While it may be mild when the mutant enzyme retains some activity [26], patients 
in this type present adult onset, mild-to-moderate hypertension, and normal potas-
sium. The diagnosis of AME is usually suspected in the setting on non-aldosterone 
dependent low-renin hypertension (LRH) with classic features of MR activation and 
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confirmed by a high cortisol/cortisone (F/E) ratio in the serum or urine, and/or genetic 
sequencing of HSD11B2 [27, 28].
It is notable that both glycyrrhizic acid and grapefruit juice are HSD11B2 inhibi-
tors and an excessive intake can induce clinical symptoms and laboratory findings 
of AME syndrome [29]. Baudrand and Vaidya conceived that lower cortisone levels 
(in combination with higher F/E ratio) were strongly associated with higher MR 
activity (lower renin activity and higher urinary potassium excretion) in patients 
suspected to have mild or non-classical AME [30].
The treatment for classic AME is low-dose dexamethasone in combination with 
MRAs or renal transplantation in extreme cases.
1.4 Congenital adrenal hyperplasia
Congenital adrenal hyperplasia (CAH) is an autosomal recessive disorder caused 
by defects in different enzymes involved in adrenal steroid production. Among 
them, the deficiency of 21-hydroxylase caused by CYP21A2 gene mutation is the 
most frequent cause of CAH (90–95%).
Affected patients present sodium loss but normal blood pressure, followed 
by 11β-hydroxylase deficiency which is caused by gene mutation of CYP11β1 
(5–8%), while the other defects are rare, including CYP17α1 gene mutation caused 
17α-hydroxylase (CYP17) deficiency [31].
The 11β-hydroxylase catalyzes the 11-deoxycortisol and 11-deoxycorticosterone 
(DOC) to cortisol and corticosterone, CYP11B1 deficiency impairs above function 
and results in low levels of cortisol and high levels of 11-deoxycortisol and 11-DOC 
and a shunting of metabolites into the androgen synthesis pathway.
Due to the mineralocorticoid function of DOC, two-thirds of the affected sub-
jects display hypertension at diagnosis, together with suppressed renin, low aldoste-
rone levels, and hypokalemia [32]. Due to the excessive androgens, patients present 
various degrees of virilization of female external genitalia and pseudo-precocious 
pubertal development in males, together with accelerated somatic growth, but 
premature closure of growth plates resulting in short stature in adulthood.
The diagnosis can be confirmed via elevated DOC and androgen levels and/
or genetic sequencing of 11β-hydroxylase. 17α-hydroxylase deficiency present a 
clinical phenotype sustained by a reduction in cortisol and adrenal and gonadal sex 
steroids production associated with an increase in DOC levels, featuring a clinical 
phenotype of mineralocorticoid excess. The deficiency of sex hormones results in 
hypogonadism in men and infantilism in women.
High levels of DOC result in MR activation, hypertension, and hypokalemia. 
Clinical examination of plasma cortisol, sex hormone precursors, and DOC is help-
ful for diagnosis, and ultrasound examination of genitals is helpful to understand 
the development of uterus, gonadal, and vagina.
Treatment involves glucocorticoid and MR antagonists to normalize blood pres-
sure and sex hormone replacement therapy [33].
1.5 Mineralocorticoid receptor activating mutations
In 2000, Geller et al. [34] first reported the single-gene genetic hyperten-
sion caused by the active mutation of mineralocorticoid receptor (MR), an 
autosomal dominant genetic disease, also known as the pregnancy aggravated 
hypertension.
Functional mutation is achieved through a substitution of leucine for serine at 
codon 810 (abbreviated as S810L) in the MR gene. The worsening in pregnancy is 
explained by the theory that progesterone activates the mutant S810L MR, where 
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progesterone typically antagonizes wild-type MR. So termination of pregnancy is a 
must for pregnant women to lower blood pressure.
While in males and non-pregnant females, cortisone and DOC activate the 
mutant MR and result in increased sodium reabsorption [35]. Surprisingly, spirono-
lactone is ineffective since its agonist effect on the mutant MR and it can increase 
MR activation paradoxically.
Treatment with sodium channel blockers such as amiloride to inhibit ENaC may 
be effective, the novel and potent nonsteroidal selective MR antagonist-finerenone 
may also be a useful option [36].
1.6 Glucocorticoid resistance syndrome
Glucocorticoid resistance syndrome (GRS) is an autosomal recessive or domi-
nant disease, caused by glucocorticoid receptor gene NR3C1 point mutation or 
deletion in the chromosome 5q31-q32 [37, 38].
Affected patients are characterized by a various degree of end-organ insensitiv-
ity to glucocorticoids, compensatory ACTH hypersecretion, excessive production 
of cortisol, adrenal androgens, and other adrenal steroids displaying mineralocorti-
coid activity. The classic phenotype of GRS is chronic fatigue and malaise, low renin 
hypertension, hypokalemia, and metabolic alkalosis.
Although female fetus virilization is extremely rare, affected children can dis-
play precocious puberty and premature adrenarche, and female patients can display 
acne, hirsutism, male pattern alopecia, and infertility.
The therapy is using overnight low-dose dexamethasone to suppress ACTH 
secretion, which improves ACTH-induced symptoms, and spironolactone can 
further help to control hypertension and female hirsutism.
1.6.1 Glucocorticoid remediable aldosteronism
Glucocorticoid remediable aldosteronism (GRA) is an autosomal dominant 
genetic disease [39], also known as familial hyperaldosteremia type I (FH-I), is the 
first identified monogenic hypertension.
CYP11B1 and CYP11B2 genes were identified as the culprit of FH-1 [40]. FH-I 
is a low renin hypertension characterized by severe early onset hypertension which 
is remediable by glucocorticoid, and is at high risk of experiencing cerebrovascular 
events at a young age, however milder phenotypes can coexist.
Stowasser et al. described the severity of the hypertension correlates with the 
sex: female subjects show a less-severe phenotype and a better prognosis [41].
GRA should be suspected when CT and other imaging examinations do not 
reveal adrenal cortical hyperplasia or tumor. Selective screening of GRA patients 
combined with typical clinical features can improve diagnostic level.
According to the Endocrine Society guideline, the diagnosis of FH-I should be 
pursued in patients younger than 20 years old with an onset of confirmed PA and in 
those who have a family history of primary aldosteronism or stroke at a young age 
(<40 years).
On the basis of positive dexamethasone suppression test as well as the 
18-hydroxycortisol >2 times the normal limit of 24 h urine or > 10 nmol/L, GRA 
may be considered; and if the chimeric genes of CYP11B2 and CYP11B1 were 
screened, the definite diagnosis can be made.
The first-line therapy is low doses of glucocorticoid, administered at bedtime 
to suppress the early morning ACTH. Treatment with mineralocorticoid receptor 
antagonist is the second line therapy, which may have same effect and avoids side 
effects of corticoid iatrogenic.
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1.6.2 Familial hyperaldosteremia type II
This type may be the most common form of familial hyperaldosteremia, and was 
first reported in 1991 by Gordon et al. [42].
Familial hyperaldosteremia type II (FH-II) is an autosomal dominant genetic 
disease with incomplete penetrance in which the pathogenic gene is located on 
chromosome 7p22, and the genetic basis has been very recently identified in germ-
line mutations in the CLCN2 gene, encoding Cl− channel ClC-2, which is expressed 
in adrenal zona glomerulosa [43].
Further studies are needed to establish the impact (in term of prevalence) of 
CLCN2 mutations on FH-II. Unlike FH-I, FH-II is not a glucocorticoid remediable 
form of primary aldosteronism, traditionally considered clinically and biochemi-
cally indistinguishable in a sporadic form. Some patients with FH-II had unilateral 
primary aldosteronism caused by aldosterone-producing adenomas and were surgi-
cally curable by unilateral adrenalectomy.
1.6.3 Familial hyperaldosteremia type III
Familial hyperaldosteremia type III (FH-III) was reported as a novel form of 
primary aldosteronism in 2008 [44] and the molecular basis is a germline mutation 
of the KCNJ5 gene, which is located on chromosome 11q24 and encodes for a K+ 
channel, GIRK4, also known as Kir3.4.
The prevalence of this disease is low, it was reported to be about 0.3% of all 
patients with primary aldosteronism. So far, 12 families and 6 germline mutations 
have been reported, most affected patients display extremely severe primary aldo-
steronism (type A) that requires bilateral adrenalectomy to control drug-resistant 
hypertension.
In 2012, 2 studies independently reported the G151E germline mutation in 
patients with milder hyperaldosteronism (type B), who had no adrenal hyperplasia 
and responded well to antihypertensive therapy.
The endocrine society guidelines recommend FH-III genetic testing (KCNJ5 
target gene sequencing) for all patients who have early onset of primary 
aldosteronism.
1.6.4 Familial hyperaldosteremia type IV
Familial hyperaldosteremia type IV (FH-IV) described by Scholl et al. [45] 
recently, is a rare form of familial primary aldosteronism. It is an autosomal 
dominant disease and caused by a germline mutation of CACNA1H, which 
locates on chromosome 16p13 and encodes for a T-type calcium channel, 
Cav3.2.
Mutations in CACNA1H showed drastically impaired channel inactivation and 
activation at more hyperpolarized potentials, increased intracellular Ca2+, and 
aldosterone production. Compared to FH-II patients affected in a sporadic form, 
this disease displays an incomplete penetrance and the affected patients did not 
display any peculiar biochemical characteristics.
1.7 Hypertension and brachydactyly syndrome
Hypertension and brachydactyly syndrome (HTNB), also named Bilginturan 
syndrome, is reported in a Turkish family by Bilginturan et al. [46] in 1973, which is 
characterized by severe salt-independent hypertension, a short stature, brachydac-
tyly, and death from stroke before the age of 50 years when untreated.
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It is autosomal dominant inheritance and full penetrance, and pathogenic genes 
at 12p12.2-p11.2 [47]. In 2015, Maass et al. [48] identified mutations in the PDE3A 
gene at 12p12.2 from 6 families with HTNB, which were heterozygous missense 
mutation.
These mutations were suggested to cause hypertension in the HTNB patients by 
increasing peripheral vascular resistance. HTNB is less reactive to β blockers, CCB, 
α blockers, and ACEI, combination therapy maybe more effective.
2. Conclusion
The disorders described above highlight the importance of the identification 
and diagnosis of monogenic hereditary hypertension. The gold standard for the 
diagnosis of monogenic forms of hypertension is gene detection. It attaches great 
significance to carry out gene detection for patients with hypertension who are 
clinically suspected.
Genetic testing can not only screen pathogenic genes to guide targeted therapy, 
but also screen the genes of the proband’s family to detect all individuals carry-
ing pathogenic genes, which is conducive to early detection, early treatment, and 
prenatal diagnosis of the disease.
Meanwhile, monogenic hypertension is a hereditary rare disease with relatively 
definite genes. The study on its genetic mechanism has greatly extended the under-
standing about the pathologic molecular mechanism of hypertension, which will 
help us to learn the correlation between hypertension and heredity more deeply.
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